Cipla Europe SA
Cipla Europe reported revenue of €24.8m for the 2025 financial year (annual accounts filed with the NBB on 08 Oct 2025).
The score of Cipla Europe shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +17 % Equity -57 % Total assets +24 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cipla Europe's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €24.8m | ||||
| Net result | −€1.32m | ||||
| Equity | €3.50m | ||||
| Cash | 929,317 € | ||||
| EBITDA | €2.04m | ||||
| Total assets | €40.8m |
Filed annual accounts
- Year ended 31 Mar 2025filed on 08 Oct 2025
- Year ended 31 Mar 2024filed on 27 Jan 2025
- Year ended 31 Mar 2023filed on 20 Dec 2023
- Year ended 31 Mar 2022filed on 22 Sep 2022
- Year ended 31 Mar 2021filed on 17 Aug 2021
Cipla Europe's financial analysis
- Solvency8.6%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cipla Europe
Cipla Europe's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0539.790.548
- VAT number
- BE0539790548
- Peppol
- Registered · 0208:0539790548 · as of 12 Nov 2026
- Legal form
- SA
- Incorporated
- 30 Sep 2013
- Registered office
- 2018 Antwerp
- Latest accounts
- 2025 · filed on 08 Oct 2025
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Cipla Europe (SA) has been based in Antwerp since 2013, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €24.8m, a net loss of €1.32m and equity of €3.50m. Its solvency stands at 8.6%, below the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Cipla Europe
Companies in the same business, of comparable size and area, outside its group.
- Teva Pharma Belgium Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €33.4m
- Kenvue Belgium Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €32.0m
- De Ceunynck Medical Wholesale of pharmaceutical and medical goods Aartselaar · balance sheet €16.9m
- Leo Pharma Wholesale of pharmaceutical and medical goods Lier · balance sheet €15.1m
- Valerco Wholesale of pharmaceutical and medical goods Kontich · balance sheet €12.9m
- Febelco Wholesale of pharmaceutical and medical goods Sint-Niklaas · balance sheet €381.9m
- Chiesi Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €32.4m
- Covetrus Wholesale of pharmaceutical and medical goods Beringen · balance sheet €37.1m
Frequently asked questions about Cipla Europe
What is the revenue of Cipla Europe?
According to the 2025 annual accounts filed with the NBB, the revenue of Cipla Europe amounts to 24,782,987 €.
What is the VAT number of Cipla Europe?
In Belgium, the VAT number is the company number prefixed with BE: BE0539790548 for Cipla Europe, if the company is VAT-registered. Its company number (CBE) is 0539.790.548.
Where is the registered office of Cipla Europe?
According to the CBE register, the registered office of Cipla Europe is in 2018 Antwerp.
What is the equity of Cipla Europe?
At the close of the 2025 financial year, the equity of Cipla Europe amounts to 3,495,902 €, a solvency of 8.6% of total assets.
Who manages Cipla Europe?
The register lists 3 active mandates at Cipla Europe. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cipla Europe
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →